Lung Cancer

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Hidehito Horinouchi, MD, PhD, discusses safety data from the ALINA trial of adjuvant alectinib in ALK-positive non–small cell lung cancer.

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail the 11-0 ODAC vote that new trial designs for perioperative regimens in resectable NSCLC should include within-trial assessment of each treatment phase's contribution.

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.